CLAIMS

1. A composition comprising maribavir and Compound 4,



maribavir



4

wherein Compound 4 is present in an amount of 0.1% w/w or less relative to maribavir.

2. The composition of claim 1, wherein Compound 4 is present in an amount of from 0.01% to 0.1% w/w relative to maribavir.

3. The composition of claim 1, wherein Compound 4 is present in an amount of 0.05% w/w or less relative to maribavir.

4. The composition of claim 3, wherein Compound 4 is present in an amount of from 0.01% to 0.05% w/w relative to maribavir.

5. The composition of any one of claims 1-4, further comprising Compound 3,



3

wherein Compound 3 is present in an amount of 0.1% w/w or less relative to maribavir.

6. The composition of claim 5, wherein Compound 3 is present in an amount of from 0.01% to 0.1% w/w relative to maribavir.

7. The composition of claim 6, wherein Compound 3 is present in an amount of from 0.01% to 0.05% w/w relative to maribavir.

8. The composition of any one of claims 1-7, further comprising Compound 2,



2

wherein Compound 2 is present in an amount of 0.1% w/w or less relative to maribavir.

9. The composition of claim 8, wherein Compound 2 is present in an amount of from 0.01% to 0.1% w/w relative to maribavir.

10. The composition of claim 9, wherein Compound 2 is present in an amount of from 0.01% to 0.05% w/w relative to maribavir.

11. The composition of any one of claims 1-10, further comprising D-maribavir, wherein D-maribavir is present in an amount of 0.1% w/w or less relative to maribavir.

12. The composition of any one of claims 1-11, wherein the maribavir has a particle size distribution (PSD) with a d(50) of between about 170 and about 350 µm.

13. The composition of claim 12, wherein the d(50) is between about 170 and about 226 µm.

14. The composition of claim 12, wherein the d(50) is between about 227 and about 280 µm.

15. The composition of claim 12, wherein the d(50) is between about 281 and about 336 µm.

16. A pharmaceutical composition comprising a composition of any one of claims 1-15 and one or more pharmaceutically acceptable excipients.